Monopar Announces First Patient Dosed in Phase 1b Trial Evaluating Camsirubicin for the Treatment of Advanced Soft Tissue Sarcoma bit.ly/2XNLKST

Monopar Therapeutics Reports Third Quarter 2021 Financial Results and Recent Clinical Developments bit.ly/30iU2Ui

Monopar Advances Dosing of Camsirubicin to Higher Level Than Tested In Any Previous Clinical Trial bit.ly/3GsWiHE

Monopar to Present at the H.C. Wainwright BioConnect Conference bit.ly/3qUPUTI

Monopar Announces Clinical and Preclinical Program Updates bit.ly/3BojsOr

Scholars join forces on anti-cancer drug: gatescambridge.org/about/news/sch…

Monopar Announces Presentation Selected for 2022 Connective Tissue Oncology Society (CTOS) Annual Meeting globenewswire.com/news-release/2…

Monopar Announces Presentation Selected for 2022 American Society of Hematology (ASH) 64th Annual Meeting globenewswire.com/news-release/2…

Monopar Announces Timeline of Upcoming Data Events for Validive, Camsirubicin, and MNPR-202 globenewswire.com/news-release/2…

Abstracts for the ASH 2022 Conference were released today, please find Monopar's here! ash.confex.com/ash/2022/webpr…

Monopar Announces Promising MNPR-202 Data from Ongoing National University of Singapore Collaboration globenewswire.com/news-release/2…

Monopar Receives Clearance to Proceed with First-in-Human Phase 1 Trial of Novel Radiopharmaceutical MNPR-101-Zr in Advanced Cancers globenewswire.com/news-release/2…

Monopar Announces Promising Preclinical Data for its MNPR-101 Radiopharma Program Targeting Advanced Cancers globenewswire.com/news-release/2…

Monopar Provides Update on MNPR-101-Zr Radiopharma Clinical Trial globenewswire.com/news-release/2…

Monopar Announces Positive Preclinical Therapeutic Isotope Data for its MNPR-101 Radiopharma Program globenewswire.com/news-release/2…

Monopar Initiates Radiopharma Phase 1 Clinical Trial for MNPR-101-Zr in Advanced Cancer Patients globenewswire.com/news-release/2…

Monopar Presents Encouraging Human Clinical Dosimetry Data on its uPAR Radiopharma Program at EANM 2024 ir.monopartx.com/press-releases…

Monopar Announces Agreement with Alexion, AstraZeneca Rare Disease For Late-Stage Wilson Disease Drug Candidate globenewswire.com/news-release/2…

Monopar Announces ALXN1840 Data Selected for Late-Breaker Presentation at EASL Congress 2025 globenewswire.com/news-release/2…

Monopar Presents ALXN1840 Late-Breaker Data at EASL 2025 globenewswire.com/news-release/2…